Doublecortin-like kinase 1 as a novel drug target and biomarker in gastrointestinal and renal cancers
Although their existence was once controversial, cancer stem cells (CSCs) are now widely accepted as an important source of metastasis and drug resistance. Recent advances in genetic engineering allowing hierarchies of cell lineages to be traced in vivo have led to the discovery of specific markers...
Main Author: | Weygant, Nathaniel |
---|---|
Other Authors: | Hafizi, Sassan |
Published: |
University of Portsmouth
2018
|
Subjects: | |
Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.749277 |
Similar Items
-
Ablation of Doublecortin-Like Kinase 1 in the Colonic Epithelium Exacerbates Dextran Sulfate Sodium-Induced Colitis.
by: Dongfeng Qu, et al.
Published: (2015-01-01) -
Elevated doublecortin-like kinase 1 serum levels revert to baseline after therapy in early stage esophageal adenocarcinoma
by: Emily M. Christman, et al.
Published: (2019-03-01) -
Autoregulatory control of microtubule binding in doublecortin-like kinase 1
by: Regina L Agulto, et al.
Published: (2021-07-01) -
Structural basis for small molecule targeting of Doublecortin Like Kinase 1 with DCLK1-IN-1
by: Onisha Patel, et al.
Published: (2021-09-01) -
Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells.
by: Dongfeng Qu, et al.
Published: (2015-01-01)